Advertisement
Advertisement
CYTK
Cytokinetics Inc.
76.06
USDSponsored
-2.58
-3.28%
May 15, 13:30 UTC -4
Open
CYTK Earnings Reports
Positive Surprise Ratio
CYTK beat 15 of 41 last estimates.
37%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$15.50M
/-$1.69
Implied change from Q1 26 (Revenue/ EPS)
-19.90%
/+1.20%
Implied change from Q2 25 (Revenue/ EPS)
-76.78%
/+50.89%
Cytokinetics Inc. earnings per share and revenue
On May 05, 2026, CYTK reported earnings of -1.67 USD per share (EPS) for Q1 26, beating the estimate of -1.68 USD, resulting in a 0.94% surprise. Revenue reached 19.36 million, compared to an expected 8.69 million, with a 122.76% difference. The market reacted with a -2.92% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -1.69 USD, with revenue projected to reach 15.50 million USD, implying an increase of 1.20% EPS, and decrease of -19.90% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
CorMedix Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
$0.37
Actual
$0.43
Surprise
+15.59%
Invivyd, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.13
Surprise
-73.80%
Autolus Therapeutics plc - ADR
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.27
Surprise
-2.94%
Pelthos Therapeutics Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$3.34
Actual
-$3.09
Surprise
+7.55%
Dogwood Therapeutics, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.15
Surprise
+42.70%
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
Elutia Inc. Class A Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
RenovoRx, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Dare Bioscience, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.20
Surprise
+32.39%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
FAQ
What were Cytokinetics Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Cytokinetics Inc. reported EPS of -$1.67, beating estimates by 0.94%, and revenue of $19.36M, 122.76% above expectations.
How did the market react to Cytokinetics Inc.'s Q1 2026 earnings?
The stock price moved down -2.92%, changed from $77.09 before the earnings release to $74.84 the day after.
When is Cytokinetics Inc. expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Cytokinetics Inc.'s next earnings report?
Based on 10
analysts, Cytokinetics Inc. is expected to report EPS of -$1.69 and revenue of $15.50M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement